183 related articles for article (PubMed ID: 22419052)
1. Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI--typical, atypical, pre- and post-treatment evaluation.
Meyers AB; Towbin AJ; Geller JI; Podberesky DJ
Pediatr Radiol; 2012 Jul; 42(7):859-66. PubMed ID: 22419052
[TBL] [Abstract][Full Text] [Related]
2. Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis.
Furlan A; Borhani AA; Heller MT; Yu RK; Tublin ME
Abdom Radiol (NY); 2016 Jul; 41(7):1399-410. PubMed ID: 26907715
[TBL] [Abstract][Full Text] [Related]
3. Characterization of pediatric liver lesions with gadoxetate disodium.
Meyers AB; Towbin AJ; Serai S; Geller JI; Podberesky DJ
Pediatr Radiol; 2011 Sep; 41(9):1183-97. PubMed ID: 21701987
[TBL] [Abstract][Full Text] [Related]
4. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
5. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
6. GADOXETATE DISODIUM (GD-EOB-DTPA) CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA IN DOGS.
Constant C; Hecht S; Craig LE; Lux CN; Cannon CM; Conklin GA
Vet Radiol Ultrasound; 2016 Nov; 57(6):594-600. PubMed ID: 27633531
[TBL] [Abstract][Full Text] [Related]
7. Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography.
Tateyama A; Fukukura Y; Takumi K; Shindo T; Kumagae Y; Kamimura K; Nakajo M
World J Gastroenterol; 2012 Nov; 18(43):6269-76. PubMed ID: 23180948
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
[TBL] [Abstract][Full Text] [Related]
9. Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
Nakamura Y; Date S; Toyota N; Tani C; Honda Y; Komoto D; Tanitame K; Awai K
J Comput Assist Tomogr; 2011; 35(3):351-2. PubMed ID: 21586929
[TBL] [Abstract][Full Text] [Related]
10. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
[TBL] [Abstract][Full Text] [Related]
11. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
12. Imaging findings of primary hepatic angiosarcoma on gadoxetate disodium-enhanced liver MRI: comparison with hepatic haemangiomas of similar size.
Kim B; Byun JH; Lee JH; Park BJ; Kwon HJ; Lee JH; Lee SJ; Won HJ; Shin YM; Kim PN
Clin Radiol; 2018 Mar; 73(3):244-253. PubMed ID: 29111237
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.
Cruite I; Schroeder M; Merkle EM; Sirlin CB
AJR Am J Roentgenol; 2010 Jul; 195(1):29-41. PubMed ID: 20566795
[TBL] [Abstract][Full Text] [Related]
14. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.
Sugimoto K; Moriyasu F; Shiraishi J; Saito K; Taira J; Saguchi T; Imai Y
Eur Radiol; 2012 Jun; 22(6):1205-13. PubMed ID: 22270142
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
Li J; Wang J; Lei L; Yuan G; He S
Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
[TBL] [Abstract][Full Text] [Related]
17. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI.
Kumada T; Toyoda H; Tada T; Sone Y; Fujimori M; Ogawa S; Ishikawa T
AJR Am J Roentgenol; 2011 Jul; 197(1):58-63. PubMed ID: 21701011
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.
Ringe KI; Husarik DB; Sirlin CB; Merkle EM
AJR Am J Roentgenol; 2010 Jul; 195(1):13-28. PubMed ID: 20566794
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging of primary pediatric liver tumors.
Pugmire BS; Towbin AJ
Pediatr Radiol; 2016 May; 46(6):764-77. PubMed ID: 27229495
[TBL] [Abstract][Full Text] [Related]
20. Pseudolesion of the liver observed on gadoxetate disodium-enhanced magnetic resonance imaging obtained shortly after transarterial chemoembolization for hepatocellular carcinoma.
Shinagawa Y; Sakamoto K; Fujimitsu R; Ida M; Urakawa H; Kora S; Higashihara H; Takano K; Yoshimitsu K
Jpn J Radiol; 2010 Jul; 28(6):483-8. PubMed ID: 20661702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
